格隆汇10月24日丨众生药业(002317.SZ)在投资者互动平台表示，公司重视药品的国外市场机会，目前 已与科兴制药达成昂拉地韦片在中国澳门地区的商业化合作，借助区域落地形成品牌海外辐射效应，助 力公司完善国际化布局，为海外拓展积累经验。公司将适时开展昂拉地韦片海外市场的拓展，探索更多 可能性，加快国际化推进步伐。公司密切关注疾病动态情况，积极做好药品生产和销售工作。 ...

格隆汇10月24日丨众生药业(002317.SZ)在投资者互动平台表示，公司重视药品的国外市场机会，目前 已与科兴制药达成昂拉地韦片在中国澳门地区的商业化合作，借助区域落地形成品牌海外辐射效应，助 力公司完善国际化布局，为海外拓展积累经验。公司将适时开展昂拉地韦片海外市场的拓展，探索更多 可能性，加快国际化推进步伐。公司密切关注疾病动态情况，积极做好药品生产和销售工作。 ...

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced a decline recently, despite a significant increase in its price year-to-date, indicating potential volatility in the market [1]. Financial Performance - As of June 30, Kexing Pharmaceutical reported a revenue of 700 million yuan, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 80.34 million yuan, showing a substantial increase of 576.45% [2]. - Cumulatively, Kexing Pharmaceutical has distributed dividends amounting to 51.54 million yuan since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2]. - The top ten circulating shareholders include notable funds such as E Fund Healthcare Industry Mixed A and others, with significant increases in holdings for some [3].

Core Insights - The successful shipment of the first batch of Bevacizumab biosimilar to Colombia marks a significant milestone for the company in deepening its presence in the Latin American market [1] Group 1: Overseas Commercialization Strategy - The company has been actively advancing the overseas registration of its collaborative products, receiving industry acclaim for its "multi-country registration" commercial efficiency [2] - The innovative "global selection + global coverage" outbound platform model has led to partnerships with several well-known pharmaceutical companies, securing over twenty key products for overseas commercialization across diverse therapeutic areas [2] - Colombia, as the fourth largest pharmaceutical market in Latin America, has seen a notable increase in the export of Chinese pharmaceutical products, with a 10.4% year-on-year growth in the first quarter of 2025 [2] Group 2: Regulatory and Market Entry - The Colombian pharmaceutical market is a key focus for the company, with the local regulatory body INVIMA's standards closely aligned with international authorities like the FDA and EMA, indicating a high level of market entry rigor [2] - The INVIMA certification is expected to facilitate the introduction of Bevacizumab in other Latin American markets, enhancing the company's overall market penetration strategy [2] Group 3: Collaborative Efforts and Future Plans - The successful commercialization of Bevacizumab overseas is attributed to the deep collaboration between the company and its partner, which ensures stringent production compliance and high product quality [3] - The company plans to continue advancing the registration of Bevacizumab in Latin America and other key markets, while also enhancing its local operational capabilities for other products [3] - The ongoing efforts aim to expand the company's international footprint and provide hope for more patients through access to essential medications [3]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688293 | 奧浦迈 | 55.19 | -4.40% | 2.11万 | 1.18亿 | | 300357 | 我武生物 | 31.63 | -3.18% | 10.07万 | 3.23亿 | | 688336 | 三生国健 | 59.60 | -2.39% | 7.34万 | 4.41亿 | | 000534 | 万泽股份 | 15.89 | -2.09% | 1 5.99万 | 9597.12万 | | 688331 | 荣昌生物 | 95.10 | -2.06% | 8.00万 | 7.91亿 | | 603590 | 康辰药业 | 49.56 | -1.84% | 2.32万 | 1.17亿 | | 600211 | 西藏药业 | 46.94 | -1.66% | 4.30万 | 2.03亿 | | 688278 | 特宝生物 | 77.31 | -1.58% | 1.75万 | 1.36亿 | | 002773 | 康弘药业 | + ...

Meeting Overview - The second extraordinary general meeting of shareholders was held on October 17, 2025, at the Innovation Technology Building in Shenzhen [5] - The meeting was convened by the board of directors and chaired by Chairman Deng Xueqin, utilizing a combination of on-site and online voting methods [2][3] Attendance - All 8 current directors attended the meeting, along with the board secretary Wang Xiaoqin and other senior management personnel [3] Resolutions Passed - The following key resolutions were approved during the meeting: - Proposal for the company to issue H-shares and list on the Hong Kong Stock Exchange [4] - Various aspects of the H-share issuance, including types and par value, issuance timing, method, scale, pricing, and target investors, were all approved [6][7] - The proposal to convert the company into an overseas fundraising joint-stock company was approved [7] - The fundraising usage plan for the H-share issuance was approved [7] - Authorization for the board of directors and its authorized personnel to handle matters related to the H-share issuance was approved [7] - Profit distribution plan prior to the H-share issuance was approved [7] - Amendments to the company's articles of association and related rules post-H-share issuance were approved [8] Legal Verification - The meeting was witnessed by Beijing Jiayuan Law Firm, confirming that the convening, procedures, and voting were in compliance with relevant laws and regulations [10]

证券代码：688136 证券简称：科兴制药 公告编号：2025-088 科兴生物制药股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 10 月 17 日 （二） 股东会召开的地点：深圳市南山区高新中一道与科技中一路交汇处创益 科技大厦 B 栋 19 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 80 | | --- | --- | | 普通股股东人数 | 80 | | 2、出席会议的股东所持有的表决权数量 | 112,192,882 | | 普通股股东所持有表决权数量 | 112,192,882 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 56.6324 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.6324 ...

北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025 年第二次临时股东会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 SRE Jites 务 所 A YUAN LAW OFFICES · 深圳 SHENZHEN·香港 HONG KONG · 广州 GUANGZHOU· 西安 XI'AN 北京 BEIJING · 上海 SHANGHAI 致:科兴生物制药股份有限公司 北京市嘉源律师事务所 关于科兴生物制药股份有限公司 2025年第二次临时股东会的 法律意见书 嘉源(2025)-04-744 北京市嘉源律师事务所(以下简称"本所")接受科兴生物制药股份有限公 司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称"《公 司法》")、《上市公司股东会规则》(以下简称"《股东会规则》")等现行 有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及 《科兴生物制药股份有限公司章程》(以下简称"《公司章程》")的有关规定, 指派本所律师对公司2025年第二次临时股东会(以下简称"本次股东会")进行 见证,并依法出具本法律意见书。 一、本次股东会的召集与 ...

每经AI快讯，10月17日，据科兴制药公众号消息，今年，公司与成都苑东生物制药股份有限公司（简 称：苑东生物）签署了战略合作协议。近日，双方就苑东生物阿帕他胺片仿制药达成印尼、埃及、沙 特、哥伦比亚等十余个国家的海外商业化独家授权，进一步深化双方合作，推动这款前列腺癌治疗领域 的重磅药物在东南亚、中东、拉美等潜力市场落地。 ...

Core Viewpoint - The stock price of Kexing Pharmaceutical has shown a significant increase of 76.53% year-to-date, but has experienced fluctuations in the short term, including a recent decline of 9.64% over the past 20 days and 17.84% over the past 60 days [2] Financial Performance - For the first half of 2025, Kexing Pharmaceutical reported a revenue of 700 million yuan, representing a year-on-year decrease of 7.82%. However, the net profit attributable to shareholders increased significantly by 576.45% to 80.34 million yuan [2] - Cumulative cash dividends since the company's A-share listing amount to 51.54 million yuan, with 15.78 million yuan distributed over the past three years [3] Stockholder Information - As of June 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2] - The top shareholders include notable funds such as E Fund Healthcare Industry Mixed A and others, with significant increases in holdings for some [3] Market Activity - Kexing Pharmaceutical's stock has been active on the market, appearing on the "Dragon and Tiger List" six times this year, with the most recent appearance on July 3 [2] - The stock price was reported at 38.45 yuan per share, with a market capitalization of 7.738 billion yuan as of October 14 [1]